Presentation and treatment of aggressive, Triple-Negative carcinosarcoma of the breast.

Autor: Vizgan N; Department of Chemistry Wesleyan University Middletown Connecticut USA., Jokar TO; St. Mary's General Hospital Passaic New Jersey USA., Enayati L; Department of Haematology/Oncology Brookdale University Hospital and Medical Center Brooklyn New York USA., Salyana M; Department of Haematology/Oncology Brookdale University Hospital and Medical Center Brooklyn New York USA., Gotlieb VK; Department of Haematology/Oncology Brookdale University Hospital and Medical Center Brooklyn New York USA.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2022 Jul 18; Vol. 10 (7), pp. e6020. Date of Electronic Publication: 2022 Jul 18 (Print Publication: 2022).
DOI: 10.1002/ccr3.6020
Abstrakt: An extremely rare form of breast cancer, breast carcinosarcoma accounts for less than a percent of all breast malignancies and is highly aggressive. Composed of both cancerous epithelial and mesenchymal cell types, breast carcinosarcoma is associated with a poor prognosis compared to more common breast cancers, and typically lack the receptors typical of other breast carcinomas, which minimize potential targets for treatment. In this case report, we discuss a 56-year-old patient affected by carcinosarcoma of the breast at a T2N1 stage, and the decision-making process that factored into her treatment plan.
Competing Interests: The authors have no conflict of interest to declare. No funding was provided for this submission.
(© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje